Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
46 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Sucampo Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Sucampo Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Sucampo Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Sucampo Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Sucampo Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Sucampo Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Sucampo Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Sucampo Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Sucampo Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Sucampo Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Sucampo Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sucampo Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Sucampo Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Sucampo Pharmaceuticals, Inc. Snapshot 5 Sucampo Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Sucampo Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Sucampo Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Sucampo Pharmaceuticals, Inc. - Pipeline Products Glance 13 Sucampo Pharmaceuticals, Inc. - Late Stage Pipeline Products 13 Pre-Registration Products/Combination Treatment Modalities 13 Filing rejected/Withdrawn Products/Combination Treatment Modalities 14 Phase III Products/Combination Treatment Modalities 15 Sucampo Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Sucampo Pharmaceuticals, Inc. - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Sucampo Pharmaceuticals, Inc. - Drug Profiles 19 lubiprostone 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 unoprostone isopropyl 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 SPI-017 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 cobiprostone 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 SPI-3608 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Sucampo Pharmaceuticals, Inc. - Pipeline Analysis 27 Sucampo Pharmaceuticals, Inc. - Pipeline Products by Target 27 Sucampo Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 29 Sucampo Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 30 Sucampo Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 31 Sucampo Pharmaceuticals, Inc. - Recent Pipeline Updates 33 Sucampo Pharmaceuticals, Inc. - Dormant Projects 42 Sucampo Pharmaceuticals, Inc. - Company Statement 43 Sucampo Pharmaceuticals, Inc. - Locations And Subsidiaries 44 Head Office 44 Other Locations & Subsidiaries 44 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 46 Disclaimer 46
List of Tables Sucampo Pharmaceuticals, Inc., Key Information 5 Sucampo Pharmaceuticals, Inc., Key Facts 5 Sucampo Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 Sucampo Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9 Sucampo Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10 Sucampo Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 11 Sucampo Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12 Sucampo Pharmaceuticals, Inc. - Pre-Registration, 2014 13 Sucampo Pharmaceuticals, Inc. - Filing rejected/Withdrawn, 2014 14 Sucampo Pharmaceuticals, Inc. - Phase III, 2014 15 Sucampo Pharmaceuticals, Inc. - Phase II, 2014 16 Sucampo Pharmaceuticals, Inc. - Phase I, 2014 17 Sucampo Pharmaceuticals, Inc. - Preclinical, 2014 18 Sucampo Pharmaceuticals, Inc. - Pipeline by Target, 2014 28 Sucampo Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 29 Sucampo Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 30 Sucampo Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 32 Sucampo Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 33 Sucampo Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 42 Sucampo Pharmaceuticals, Inc., Subsidiaries 44
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.